...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith-Oncology Pipeline

Narmac, I would also add that some credit for broader business development at Zenith should likely go to Sanjay Lakhotia, he has a great deal of applicable education and biotech experience. It would be refreshing to hear from him once in a while. 

Share
New Message
Please login to post a reply